This single-blinded, randomized controlled trial evaluated the efficacy of a 2-week Transcranial Pulse Stimulation (TPS) treatment on adults with major depressive disorder (MDD). Thirty participants (aged 18-54) were randomized into TPS or waitlist control (WC) groups. The primary outcome, assessed by the Hamilton Depression Rating Scale-17 (HDRS-17), showed a significant reduction in depressive symptom severity in the TPS group compared to the WC group (mean difference = −6.60, p = 0.02, Cohen's d = −0.93). This effect was large and sustained at the 3-month follow-up, indicating TPS's effectiveness in reducing depressive symptoms in adults with MDD.
Publisher
International Journal of Environmental Research and Public Health
Published On
Jan 28, 2023
Authors
Lucia Carboni, Paul B Tchounwou, Teris Cheung, Tim Man, Ho Li, Yuen Shan Ho, Georg Kranz, Kenneth N K Fong, Sau Fong Leung, Simon Ching Lam, Wing Fai Yeung, Joyce Yuen, Ting Lam, Hin Kwan Fong, Roland Beisteiner, Yu-Tao Xiang, Calvin Pak, Wing Cheng
Tags
Transcranial Pulse Stimulation
major depressive disorder
randomized controlled trial
depression treatment
Hamilton Depression Rating Scale
efficacy
clinical outcomes
Related Publications
Explore these studies to deepen your understanding of the subject.
